Most people who stop GLP-1 drugs like Ozempic eventually return

MAP Verified Summary — reported by Science Daily

Many people prescribed GLP-1 drugs for type 2 diabetes (such as Victoza, Ozempic, or tirzepatide) stop taking them, but a surprising number later return to treatment. Researchers found that newer medications appear to keep patients on therapy longer, while side effects remain a major reason for discontinuation.

This story’s context record documents 7 observable dimensions — Origin, Attribution, Specificity, Timing, Framing, Context Change, and Information Relationships — as part of Media Alert Press’s context-documentation ledger. MAP does not score or rate this content. Read the full original story at Science Daily →

View MAP Context →